Current Protein & Peptide Science publishes reviews and nothing else. Original papers, research articles and short communications are excluded by the scope statement itself.《Current Protein & Peptide Science》只发综述。原创论文、研究论文与短通讯，被范围说明本身排除在外。
The subject is proteins and peptides, taken broadly. Structure and function come first, then the interactions that make a protein interesting to anybody else.主题是蛋白质与肽，取的是宽口径。先讲结构与功能，再讲让旁人关心某个蛋白的那些相互作用。
Enzymes, hormone-receptor binding and the transcription factors that regulate gene expression are the named examples in the scope. Each of them can carry a review on its own.范围里点名的例子是酶、激素与受体的结合，以及调控基因表达的转录因子。每一样都能单独撑起一篇综述。
Peptide therapeutics is a standing category. A 2026 review works through antimicrobial peptides from design through mechanism to clinical application in one article.肽类治疗是常设类别。2026 年一篇综述在一篇文章里走完抗菌肽的设计、机理与临床应用。
Analytical chemistry has a home here. Mass spectrometric analysis of proteins and peptides, and mass spectrometry imaging applied to neuropeptidomics, are both inside the brief.分析化学在这里有位置。蛋白质与肽的质谱分析，以及用于神经肽组学的质谱成像，都在收录范围内。
Prediction and design are treated as protein science. Machine learning for anticancer peptide design and for subchloroplast localisation of proteins appear in different volumes.预测与设计被当作蛋白质科学的一部分。用机器学习设计抗癌肽，用机器学习判断蛋白的亚叶绿体定位，分处不同卷次。
Clinical reviews are built around a molecule rather than a disease. Neurotoxic amyloid beta in Alzheimer's disease and AMPK as a therapeutic target are two such titles.临床类综述围绕分子搭架，而不是围绕疾病。阿尔茨海默病里的神经毒性淀粉样蛋白、作为治疗靶点的 AMPK，是两个这样的题目。
Metabolic chemistry gets consistent space. Glyoxalase in glycation and carbonyl stress, and oxidative stress in autoimmune disease, are both treated as protein-level problems.代谢化学占的空间稳定。糖化与羰基应激里的乙二醛酶、自身免疫病中的氧化应激，都按蛋白质层面的问题来处理。
Nutrition and plant biology reach the journal through peptides and protein function. Dietary polyphenols interacting with gut components and melatonin against environmental plant stressors both appeared.营养学与植物生物学经由肽与蛋白功能进入这份刊物。膳食多酚与肠道成分的相互作用、褪黑素对抗环境胁迫，都出现过。
Infection is inside the remit. RNA sensors and innate immune evasion across SARS-CoV-2, HIV and Nipah virus were reviewed together, which is the kind of comparison a review journal exists to make.感染也在范围里。RNA 传感器与先天免疫逃逸，在 SARS-CoV-2、HIV 与尼帕病毒之间合起来写过，这正是综述刊物存在的理由。
Proteomics as a discovery tool is covered as method. What proteomics can say about COVID-19 infection, and mass spectrometry as a route to new protein biomarkers, are recent examples.作为发现工具的蛋白质组学按方法来写。蛋白质组学能说明新冠感染的什么，质谱如何通往新的蛋白标志物，是近期例子。
The brief asks for coverage rather than novelty. A submitted manuscript should survey a field by discussing work from the leading laboratories in it.这份征稿要求的是覆盖面，不是新意。来稿要讨论该领域主要实验室的工作，从而把一个方向梳理一遍。
Biomarkers get their own treatment. A review on peptide biomarkers as a diagnostic tool, and the assays that go with them, appeared in a recent volume.标志物自成一路。肽类标志物作为诊断工具的一篇综述，连同与之配套的检测方法，出现在近期卷次里。
The journal is not open access. Gold open access accounts for about one article in seventy, and the rest of the content is read through subscription and site licences.刊物不是开放获取。金色开放获取约占七十分之一，其余内容靠订阅与站点许可阅读。
History
Volume 1 is dated 2000. MEDLINE and Index Medicus took the title from the first issue in July of that year, which is early indexation for a new launch.第 1 卷标着 2000 年。同年七月出版的首期就被 MEDLINE 与《Index Medicus》收进去，新刊能有这样的收录算早。
Volume equals year minus 1999. The 2026 volume is 27, and the arithmetic has held for the whole run.卷号等于年份减 1999。2026 年是第 27 卷，这道算术从头到尾没有变过。
Frequency changed in 2017. The catalogue records twelve issues a year from that point, and the journal's own listing before it says bimonthly.出版频率在 2017 年改过。目录从那时起记作一年十二期，刊物自己更早的说明写的是双月刊。
PubMed holds 1,825 records for the title. The yearly count is 75 in 2014, 77 in 2015 and 80 in 2016, then 121 in 2017 and 116 in 2018.PubMed 里这份刊物的记录有 1825 条。逐年是 2014 年 75 条、2015 年 77 条、2016 年 80 条，2017 年跳到 121 条，2018 年 116 条。
The switch to twelve issues shows in those numbers. 2019 equals 2017 at 121 records, and the two years between hold above 110 each.改成十二期在数字里看得见。2019 年与 2017 年同为 121 条，中间两年都在 110 条以上。
Then it falls. 2021 gives 66 records, and the years since run 73, 69, 64 and 73, with 86 already filed for 2026.随后就掉下来。2021 年是 66 条，此后的年份依次是 73、69、64、73 条，2026 年已经存了 86 条。
Crossref tells a different story. Only seventeen records are deposited for the title, and several of them are the same article filed twice under the two ISSNs.Crossref 讲的是另一回事。这份刊物只存了十七条记录，其中几条还是同一篇文章按两个 ISSN 各存了一遍。
The digital identifiers have changed shape twice. Older ones carry a text stem, newer ones begin with the ISSN digits and end with a date and serial number.数字标识改过两次形状。较早的带一串字母主干，较新的以 ISSN 数字开头，末尾是日期与序号。
The imprint has moved. The catalogue's first address is Hilversum and Boca Raton, and the current one is the Saif Zone in Sharjah.出版地搬过。目录里最早的地址是希尔弗瑟姆与博卡拉顿，现在的是沙迦自贸区。
The title sits in the Science Citation Index Expanded rather than the emerging index, so it has been inside the main citation system for most of its life.这份刊物在科学引文索引扩展版里，不在新兴索引里，大半辈子都在主引文系统之内。
The name follows a house pattern. The publisher's Current series supplies the first word, and the rest of the title names the subject rather than the method.刊名沿用出版方的系列规则。第一词来自那套 Current 系列，后面写的是学科，不是方法。
Its impact factor has moved a long way. 3.272 in 2021 and 3.118 in 2022 fell to 1.9 in 2023, then 2.0 in 2024 and 2.4 in 2025.影响因子走了一大段。2021 年 3.272、2022 年 3.118，2023 年落到 1.9，之后 2024 年 2.0、2025 年 2.4。
The five-year figure is 2.8, well above the current year. A review journal's older papers keep being cited, so its long window always looks better than its short one.五年值是 2.8，明显高于当年值。综述刊的旧文章一直在被引，所以它的长窗口总比短窗口好看。
Behind 2.4 sit 3,702 citations, a half-life of 8 years and a JCI of 0.21. The percentile is 25.8, at 244 of 328 titles in biochemistry and molecular biology.2.4 背后是 3702 次引用，半衰期 8 年，JCI 为 0.21。百分位 25.8，生化与分子生物学 328 种刊物中排第 244。
Editors
The editorial office is the publisher's. Bentham runs the journal from Sharjah, and the address on file is Executive Suite Y26 in the Saif Zone.编辑部属于出版方。Bentham 从沙迦经营这份刊物，档案里的地址是自贸区 Y26 行政套房。
The board has a page of its own on the publisher's site, and the author guidelines sit beside it under the journal's four-letter code.编委会在出版方站点上有自己的页面，作者指南就摆在旁边，都用刊物那个四字母代码定位。
The masthead is not reproduced in the bibliographic record. A reader looking for the editor's name has to leave the index and go to the publisher's page.编委名单没有进书目记录。想找主编名字的读者得离开索引，去出版方的页面上找。
A review-only brief makes the job one of commissioning. Since unsolicited research is refused at the door, most of the content starts as an invitation.只发综述意味着这份工作是组稿。既然原创研究在门口就被挡下，大部分内容是从一封邀约开始的。
The scope tells the invited author what is expected. Coverage of a field, discussion of the leading laboratories, and no new data to defend.范围说明告诉受邀作者要交什么。把一个方向覆盖住，讨论该领域的主要实验室，不需要为任何新数据辩护。
That makes review simpler in one respect. There are no methods to check and no statistics to audit, so the report is about balance, accuracy and whether the literature was actually read.这让评审在某一方面变简单。没有方法要核，没有统计要审，评审意见谈的是平衡、准确，以及文献到底读没读。
Clustering happens at issue level. A single issue has carried a review of peptide biomarkers beside one on chitosan-peptide composites for tissue engineering.聚类发生在期这一层。同一期里，肽类标志物的综述与壳聚糖肽复合材料用于组织工程的综述排在一起。
Indexation was secured at launch. MEDLINE coverage from the first issue is an editorial result, since a new title has to be selected before it can appear at all.收录在创刊时就拿到了。首期即被 MEDLINE 覆盖是编辑工作的结果，新刊得先被选中才谈得上出现。
The move to twelve issues in 2017 doubled the desk's capacity and its obligations. More slots means more commissioning, and a thinner issue is harder to hide.2017 年改成十二期，把这张桌子的容量与义务一起翻倍。位置多了要组的稿就多，而一期变薄更难遮掩。
An eight-year citation half-life suits the genre. A review published a decade ago is still an entry point to its field, which is what the editor is buying when the invitation goes out.八年的引用半衰期与这个文类相配。十年前发的综述仍是进入某个方向的门，这正是编辑发出邀约时买下的东西。
The impact factor's fall and partial recovery is not explained by anything visible in the record. A review market moved, and the title moved with it.影响因子的下落与部分回升，记录里找不到解释。是综述市场在动，这份刊物跟着动。
A board in a review journal is also an invitation list. With 27 volumes behind it, most groups working on a given peptide have been asked at least once.综述刊的编委会同时是一份邀约名单。办了 27 卷，凡在某个肽上做事的团队，多半都被问过一次。